Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;38(8-9):486-492.
doi: 10.1080/07357907.2020.1811301. Epub 2020 Sep 14.

A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

Manoj Gupta  1   2 , G Karthikeyan  3 , P S Choudhury  1 , Venkata Pradeep Babu Koyyala  4 , Manish Sharma  4 , Parveen Jain  4 , Vineet Talwar  4 , Amitabh Singh  5 , Sudhir Rawal  5
Affiliations
Review

A Walk with Lu-177 PSMA: How Close we Have Reached from Bench to Bedside?

Manoj Gupta et al. Cancer Invest. 2020 Sep.

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) is a natural sequela in advanced prostate cancer following resistance to standard treatment regimes, where patients develop with rising PSA, bone pains, and high disease volume. Further palliative treatment is the need of the hour for ensuring disease control and quality of life. In recent times, many novel methods have been evolved for these patients. Endo-radioligand therapy with Lutetium 177 prostate-specific membrane antigen 617 (Lu-177 PSMA) based on the Theranostic concept has emerged as a promising tool among these. We present here the current status of Lu177-PSMA for mCRPC patient and future directions.

Keywords: Bench to bedside; Lu-177 PSMA; Metastatic castration-resistant prostate cancer; Radioligand therapy; Theranostic.

PubMed Disclaimer

MeSH terms

LinkOut - more resources